A Prescription Drug User Fee Act target date of May 27, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

pyruvate carboxylase deficiency; PA, propionic acidemia; THAN, transient hyperammonemia of the newborn; VLCADD, very long chain acyl-CoA dehydrogenase deficiency. Adapted with permission from ...

Understanding the molecular mechanisms of insulin resistance remains a major medical challenge of the twenty-first century. Over the last half-century, many hypotheses have been proposed to ...

Objective Patients with increased PD-L1 + host cells in tumours are more potent to benefit from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the underlying mechanism is ...